CClinicalTrials.gg
CompletedNCT03292471Updated Dec 20, 2022Results posted

Effects of rTMS on Brain Activation in Aphasia

An interventional study of Transcranial Magnetic Stimulation in Aphasia, Acquired, sponsored by VA Office of Research and Development. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-12-20.

Sponsored by VA Office of Research and Development · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will investigate the use of repetitive transcranial magnetic stimulation (rTMS), a non-invasive brain stimulation method, to improve word-finding abilities in Veterans and non-Veterans with chronic language problems following stroke (aphasia). Improving word-finding is important because word-finding difficulties are among the most common and debilitating consequences of aphasia. Although rTMS has shown promise as a treatment approach, not all individuals with aphasia show the same level of benefit. Specifically, this study will use functional magnetic resonance imaging (fMRI) to examine whether the likelihood of improved word-finding abilities following rTMS depends on pre-intervention language-related brain activity and will examine changes in brain activity in response to stimulation. A better understanding of how and for whom rTMS works will 1) help to identify the best candidates for rTMS treatment, 2) optimize rTMS treatment protocols to improve patient outcomes, and 3) improve the investigators' understanding of how the brain re-organizes language functions following stroke.

Read the detailed description

Aphasia, an acquired communication disorder, is a common consequence of left-hemisphere stroke. Persisting, or chronic, aphasia negatively impacts not only interpersonal communication but participation in activities of daily living, independence, and autonomy. It is also associated with higher rates of depression and lower quality of life. Therefore, examining factors and treatments that result in the best possible recovery of language function for individuals with chronic aphasia is of paramount importance.

An intervention approach that has shown promise in early-phase research on treatment of chronic aphasia is repetitive transcranial magnetic stimulation (rTMS). rTMS is a non-invasive brain stimulation technique that can be used to focally modulate activity in targeted brain regions. Studies have shown that multiple sessions of 1Hz inhibitory rTMS applied to the right hemisphere Pars Triangularis (PTr) of people with chronic aphasia results in improved naming abilities. These improvements accrue over time, and may persist even after rTMS has ended. It has been proposed that rTMS induces this improvement by reducing the disruptive influence of compensatory activity in the right hemisphere PTr, allowing for recruitment of more efficient left hemisphere peri-lesional brain areas. However, existing neuroimaging evidence to support this hypothesis is insufficient.

The goal of the proposed study is to investigate the neurological mechanisms underlying the effect of rTMS on naming performance in chronic aphasia. This will extend existing knowledge regarding hemispheric contributions to language recovery following stroke and elucidate how rTMS-induced neuroplasticity can be co-opted to encourage optimal reorganization. The study will also investigate a potential source of individual response variability to rTMS, one which can inform both candidate selection and optimal stimulation parameters. Sixteen participants will be enrolled, yielding a significantly larger sample size than previous studies that have examined changes in functional brain activation in response to rTMS (n = 1, 2).

All participants will receive a sequence of 1200 pulses of 1 Hz rTMS to right hemisphere PTr across 10 daily sessions. Half of the participants will also receive a 6 Hz rTMS excitatory priming pulse sequence immediately prior to the 1 Hz sequence. This priming sequence ensures a consistent inhibitory response to the subsequent 1Hz rTMS and will permit an examination of state-dependent individual response variability.

To evaluate the effect of rTMS over time, participants will undergo functional magnetic resonance (fMRI) scans at four time points: prior to initiation of rTMS ("baseline"), immediately following the first rTMS session ("post-rTMS"), following the conclusion of the rTMS series ("post-treatment") and at a 2-month follow-up visit. During the scans, participants will be asked to name pictures, and both patterns of regional naming-related activation and effective connectivity (directional causal influence between activated brain regions) will be evaluated at each time point. In addition, naming performance will be measured via standardized assessments at baseline, post-treatment, and follow-up.

Changes in naming performance will be assessed over time, as a measure of rTMS effectiveness overall and between groups (priming sequence vs no priming sequence). In addition, changes in activation and effective connectivity will be correlated with naming improvement to assess the relative effectiveness of right hemisphere recruitment compared to left hemisphere peri-lesional recruitment. Overall increases in left hemisphere recruitment are hypothesized to result in greater improvements. However, the magnitude of left hemisphere recruitment due to rTMS is expected to depend on baseline levels of right hemisphere PTr activity.

Results from this study will significantly improve the investigator's understanding of the effects of rTMS on stroke recovery. The results will also inform future studies evaluating rTMS as an adjunct to behavioral speech-language intervention, augmenting therapeutic gains from traditional aphasia treatment.

02

Conditions studied

  • Aphasia, Acquired

Browse trials for

Keywords

  • Aphasia
  • Rehabilitation
  • Stroke
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Aphasia due to unilateral left-hemisphere stroke
  • Greater than 6 months post aphasia onset
  • English as a first language
  • No contraindications to MRI or TMS including:

    • pregnancy
    • presence of ferromagnetic substances in the head with the exception of dental fillings, stents or aneurysm clips documented to be MRI compatible
    • presence of any implanted devices including cardiac pacemaker, implanted cardiac defibrillator, insulin pump, cochlear implant, or drug infusion device
    • history of epilepsy; use of medications that are known to lower seizure threshold
    • severe claustrophobia

Exclusion criteria

Exclusion Criteria:

  • History for progressive neurological disease or premorbid language disorder
  • Presence of severe motor speech disorder
  • Drug or alcohol dependence, or significant mood or behavioral disorder that is not currently stable or medically managed
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Inhibitory only

    Inhibitory 1Hz rTMS will be applied continuously for 1200 pulses (20 minutes) 5 days per week across 2 weeks (10 sessions total).

    Device: Transcranial Magnetic Stimulation

  • Experimental
    Excitatory primed

    The inhibitory sequence described above will be preceded for each session by priming stimulation which will consist of intermittent 6-Hz rTMS applied in 5 second trains with 25 second intervals between trains for a total 600 pulses (10 minutes).

    Device: Transcranial Magnetic Stimulation

Interventions

  • DeviceTranscranial Magnetic Stimulation

    rTMS is a non-invasive brain stimulation technique in which a focal, time-varying magnetic field is applied to a specific brain area to induce neuronal depolarization. rTMS can be used to selectively target a given brain region with a resolution as focal as 0.5 cm3 .Typically, administering a slow (1 Hz) sequence of magnetic pulses via rTMS temporarily reduces cortical excitability in the targeted brain region.

    Also known as: rTMS

05

What researchers measure

Primary outcomes

  1. Change in Philadelphia Naming Test (PNT) Performance

    The Philadelphia Naming Test is a performance-based measure commonly used to assess naming (word production) ability among adults with aphasia. The minimum raw score is 0 and the maximum is 175 (higher scores reflect more accurate naming/better naming ability).

    Time frame: Pre- to post treatment (an average of 3 weeks), and at 2 month follow-up

Secondary outcomes

  1. Change in Comprehensive Aphasia Test (CAT) Performance

    The Comprehensive Aphasia Test is a performance-based measure of language processing across multiple language domains commonly used to assess language-processing ability among adults with aphasia. CAT mean modality T-Score (average of all language subscale T-scores of the Comprehensive Aphasia Test) is a measure of overall aphasia severity. A T-score of 50 reflects mean performance for the CAT normative sample of individuals with aphasia, with a standard deviation of 10 (higher scores reflect better performance/less severe aphasia).

    Time frame: Pre- to post treatment (an average of 3 weeks), and at 2 month follow-up

06

Results

Posted Jan 21, 2022
Limitations and caveats
Unable to collect all planned functional MRI data due to technical difficulties/scanner out of service.

Participant flow

Participant flow — Overall Study
MilestoneInhibitory OnlyExcitatory Primed
Started88
Completed88
Not completed00

Outcome measures

PrimaryChange in Philadelphia Naming Test (PNT) Performance

The Philadelphia Naming Test is a performance-based measure commonly used to assess naming (word production) ability among adults with aphasia. The minimum raw score is 0 and the maximum is 175 (higher scores reflect more accurate naming/better naming ability).

Time frame:
Pre- to post treatment (an average of 3 weeks), and at 2 month follow-up
Reported as:
Mean · Score on a scale
Change in Philadelphia Naming Test (PNT) Performance
Score on a scaleInhibitory OnlyExcitatory Primed
Pre-treatment122.125 ± 27.18130.875 ± 22.86
Post-treatment132.5 ± 28.65142.125 ± 16.71
Follow-up115.6 ± 21.85133.6 ± 26.84
Statistical analysis
  • Inhibitory Only vs Excitatory Primed · Highest density interval of posterior di: .284 · 95% CI -2.07 to 2.92Direction of comparison: Group A (Standard Protocol) and post-treatment timepoint were set as reference values
  • Inhibitory Only vs Excitatory Primed · Highest density interval of posterior di: .02 · 95% CI -2.38 to 2.46Direction of comparison: Group A (Standard Protocol) and follow-up (2 months post-treatment) timepoint were set as reference values
SecondaryChange in Comprehensive Aphasia Test (CAT) Performance

The Comprehensive Aphasia Test is a performance-based measure of language processing across multiple language domains commonly used to assess language-processing ability among adults with aphasia. CAT mean modality T-Score (average of all language subscale T-scores of the Comprehensive Aphasia Test) is a measure of overall aphasia severity. A T-score of 50 reflects mean performance for the CAT normative sample of individuals with aphasia, with a standard deviation of 10 (higher scores reflect better performance/less severe aphasia).

Time frame:
Pre- to post treatment (an average of 3 weeks), and at 2 month follow-up
Reported as:
Mean · T-Score
Change in Comprehensive Aphasia Test (CAT) Performance
T-ScoreInhibitory OnlyExcitatory Primed
Pre-treatment53.56 ± 5.2553.875 ± 4.29
Post-treatment54.54 ± 5.4555.71 ± 4.59
Follow-up52.5 ± 4.0456.7 ± 5.3
Statistical analysis
  • Inhibitory Only vs Excitatory Primed · Highest density interval of posterior di: .997 · 95% CI -0.0719 to 2.25Direction of comparison: Group A (Standard Protocol) and post-treatment timepoint were set as reference values
  • Inhibitory Only vs Excitatory Primed · Highest density interval of posterior di: .443 · 95% CI -0.596 to 1.58Direction of comparison: Group A (Standard Protocol) and follow-up (2 months post-treatment) timepoint were set as reference values

Adverse events

Collected over Approximately 3 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Inhibitory Only0/8 (0%)0/8 (0%)0/8 (0%)
Excitatory Primed0/8 (0%)0/8 (0%)1/8 (12.5%)
Most frequent other events
Most frequent other events
EventInhibitory OnlyExcitatory Primed
Mild HeadacheGeneral disorders0/81/8

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Inhibitory OnlyExcitatory PrimedTotal
<=18 years000
Between 18 and 65 years538
>=65 years358
Sex: Female, Male
Sex: Female, Male(Participants)Inhibitory OnlyExcitatory PrimedTotal
Female123
Male7613
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Inhibitory OnlyExcitatory PrimedTotal
Hispanic or Latino000
Not Hispanic or Latino8816
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Inhibitory OnlyExcitatory PrimedTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American224
White6612
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Inhibitory OnlyExcitatory PrimedTotal
United States8816
Aphasia Severity (Comprehensive Aphasia Severity Mean Modality T-Score)
Aphasia Severity (Comprehensive Aphasia Severity Mean Modality T-Score)(T-Score)Inhibitory OnlyExcitatory PrimedTotal
Mean53.56 ± 5.2553.86 ± 4.2953.64 ± 4.67
07

Study locations

1 site
  • VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA
    Pittsburgh, Pennsylvania 15240, United States
08

References and documents

Study documents

  • Protocol and statistical analysis plan · Mar 6, 2017
  • Informed consent form · Jan 28, 2019

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Registry details

Key details

Study ID
NCT03292471
Lead sponsor
VA Office of Research and Development
Responsible party
Sponsor
First posted
Sep 25, 2017
Start date
Jan 1, 2018
Primary completion
Dec 31, 2019
Completion
Dec 31, 2019
Results posted
Jan 21, 2022
Last update
Dec 20, 2022

Study contacts

Michelle L. Gravier, PhD
principal investigator · VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion